# The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa

> **NCT00320567** · PHASE2 · COMPLETED · sponsor: **McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.** · enrollment: 123 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** norgestimate/ethinyl estradiol

## Key facts

- **NCT ID:** NCT00320567
- **Lead sponsor:** McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2011-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320567, "The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00320567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*